Low-Dose Tamoxifen Shows Continued Efficacy in Adjuvant Setting at 10-Year Follow-Up
Long-term data support a de-escalated dose of tamoxifen for certain women with breast intraepithelial neoplasia who are unable to receive the standard dose.
Carroll Highlights Data Presented at SABCS from the CARRIERS and RIGHT Choice Studies
Jamie Carroll, APRN, CNP, MSN, offers her perspective on emerging data from the 2022 San Antonio Breast Cancer Symposium.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
Emerging Data Showcases Promising Advancements for Patients With HER2-Low Breast Cancer
Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP, reflects on data presented at the San Antonio Breast Cancer Symposium.
Sacituzumab Govitecan Continues to Prolong Survival in Patients With HR+/HER2– Breast Cancer
Patients with hormone receptor–positive, HER2-negative metastatic breast cancer derived benefit with sacituzumab govitecan regardless of Trop-2 expression.
POSITIVE Study Findings Shift Conversations on Pregnancy in ER+ Breast Cancer
Jamie Carroll, APRN, CNP, MSN, weighs in on how findings from the POSITIVE study may change dialogue surrounding pregnancy for women with estrogen receptor–positive breast cancer who wish to pause adjuvant therapy.
CBD Oil Shows Modest Improvements in Tamoxifen-Related Adverse Effects
Cannabidiol oil may be useful in helping patients with breast cancer manage tamoxifen-related adverse effects.
Antidiarrheal Prophylaxis Remains a Key Focus in TKI Treatment for Patients with HER2+ Breast Cancer
Loperamide prophylaxis was linked to low rates of grade 3 diarrhea in patients receiving adjuvant pyrotinib, but better antidiarrheal prophylaxis options are still needed in this setting.
Black Women With HR+ Breast Cancer Experience Inferior Outcomes, Despite Comparable Recurrence Scores
Non-Hispanic Black patients with hormone receptor (HR)–positive/HER2-negative breast cancer were more likely to have worse outcomes vs non-Hispanic White, Asian, and Hispanic patients, even with similar 21-gene recurrence scores.
Real-World Data Show Neoadjuvant Pertuzumab/Trastuzumab Increases pCR Rates in HER2+ Breast Cancer
Neoadjuvant pertuzumab/trastuzumab increased the rate of pathological complete response in patients with HER2-positive breast cancer.
Grace Choong and Matthew Goetz On the Impact of Adjuvant Endocrine Therapy Omission in ER+ Positive Breast Cancer
Grace Choong, MD; and Matthew Goetz, MD, discuss the effect of omitting adjuvant endocrine therapy for patients with estrogen receptor–positive breast cancer who were treated with neoadjuvant chemotherapy.
Chemotherapy Plus Endocrine Therapy Increases Cognitive Impairment in Breast Cancer
Patients with breast cancer may be at risk for more intense cognitive impairment following treatment with chemotherapy plus endocrine therapy.
Camizestrant Emerges As A Potentially Effective Oral SERD for Patients With HER2-Negative Advanced Breast Cancer
Camizestrant doubled progression-free survival compared with fulvestrant in patients with estrogen receptor–positive, HER2-negative advanced breast cancer.
Adjuvant T-DM1 With Concurrent Radiotherapy Is Not Associated with Cardiotoxic Concerns in Early-Stage HER2+ Breast Cancer
Patients with early-stage, HER2-positive breast cancer who received both adjuvant ado-trastuzumab emtansine and concurrent radiotherapy did not experience a significant drop in ejection fraction or global longitudinal strain.
Capivasertib/Fulvestrant Boosts Progression-Free Survival in HR+/HER2– Breast Cancer
Capivasertib plus fulvestrant improved progression-free survival in patients who have hormone-receptor–positive/HER2-negative advanced breast cancer.
Ribociclib Plus Endocrine Therapy Reduces Disease Progression in HR+/HR- Advanced Breast Cancer
Ribociclib showed a significant reduction in risk of disease progression in patients with pre- and perimenopausal HR+, HR- advanced breast cancer.
Improved PFS Outcomes With Elacestrant Correlate With CDK4/6 Duration in ER+/HER2– Metastatic Breast Cancer
Longer duration of CDK4/6 inhibitor prior to treatment with elacestrant correlated with progression-free survival (PFS) improvements in patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer vs standard-of-care options.
Adjuvant Chemotherapy Does Not Significantly Increase Breast Cancer-Related Lymphedema Risk
Treatment with chemotherapy, including taxane-based chemotherapies, in the adjuvant setting did not yield significant differences in breast-cancer related lymphedema risk.
Ovarian Suppression Treatment Is Rare for Premenopausal Women with HR+/HER2+ Breast Cancer
In real-world practice, use of ovarian suppression therapy was not common among premenopausal patients with hormone receptor–positive, HER2-positive breast cancer, with tamoxifen being the preferred endocrine therapy.
DESTINY-Breast02 Confirms Benefit of Trastuzumab Deruxtecan in Previously Treated Patients With HER2+ Metastatic Breast Cancer
In the second-line setting, patients with advanced HER2-positive breast cancer derived a superior clinical benefit with trastuzumab deruxtecan compared with treatment with physician’s choice of treatment.
Patients With HR+ Breast Cancer May Safely Pause Endocrine Therapy to Pursue Pregnancy
Findings from the POSITIVE trial suggest that pausing endocrine therapy to pursue pregnancy did not negatively affect outcomes for patients with breast cancer.
Adjuvant Abemaciclib Plus Endocrine Therapy Sustains Benefit for Patients With HR+/HER2– High-Risk Early Breast Cancer
A landmark 4-year analysis of invasive-disease free survival outcomes from the phase 3 monarchE study support the use of adjuvant abemaciclib with endocrine therapy for patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer.
Trastuzumab Deruxtecan Outperforms Trastuzumab Emtansine in DESTINY-Breast03 Follow-Up
Trastuzumab deruxtecan both significantly improved overall survival and yielded progression-free survival that was 4 times greater than trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.
Neoadjuvant Trastuzumab Deruxtecan Displays Clinical Activity in Localized HR+, HER2-Low Breast Cancer
New findings suggest that neoadjuvant therapy with antibody-drug conjugates may be effective for patients with early-stage breast cancer.
Patients With HER2+ Breast Cancer and Brain Metastases Achieve Better OS With Tucatinib Triplet Regimen
A triplet regimen of tucatinib, trastuzumab, and capecitabine helped patients with HER2-positive metastatic breast cancer and brain metastases live longer with reduced disease progression compared with trastuzumab and capecitabine alone.
Genomic Alterations in Primary Breast Cancer May Increase Risk of Secondary Uterine Cancer in Patients Receiving Tamoxifen
PI3K-pathway mutations may predict an increased risk of secondary uterine cancer in patients receiving tamoxifen to treat primary breast cancer.
Forgoing Select Lymph Node Dissection Linked With Superior Outcomes in Early-Stage Breast Cancer
Updates from the ongoing INSEMA trial suggest that patients with early-stage breast cancer maintain superior quality of life by forgoing sentinel lymph node biopsy and axillary lymph node dissection.
pCR Rates Following Neoadjuvant Therapy Similar Between Black and White Women With Breast Cancer
Findings from a breast cancer analysis demonstrated that pathologic complete response and event-free survival rates were not significantly affected by patient’s race.
Adjuvant Neratinib or T-DM1 Decreases Distant Recurrence Risk in HER2+ Early-Stage Breast Cancer
The introduction of adjuvant approaches reduced the risk of disease recurrence in HER2-positive, early-stage breast cancer.
Black Patients With Breast Cancer Experience Higher Rate of Treatment Modifications or Discontinuations
Treatment modifications were inconsistent among White and Black patients with breast cancer. However, the use of a multiscale biophysical modeling platform may be useful in informing treatment modification decisions.
Olanzapine Significantly Reduces CINV in Patients Receiving MEC
Reimagining Frailty Screenings in Head and Neck Cancer
Screening for Pain and Depression is Not Enough in Cancer Care
Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPC
2 Clarke Drive Cranbury, NJ 08512